TrialInflammatory bowel diseases2026

Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.

Marla C Dubinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.